Neuland Laboratories Ltd
NSE:NEULANDLAB

Watchlist Manager
Neuland Laboratories Ltd Logo
Neuland Laboratories Ltd
NSE:NEULANDLAB
Watchlist
Price: 15 276 INR 1.43%
Market Cap: 196B INR

Neuland Laboratories Ltd
Total Equity

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Neuland Laboratories Ltd
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
Neuland Laboratories Ltd
NSE:NEULANDLAB
Total Equity
₹16.2B
CAGR 3-Years
22%
CAGR 5-Years
17%
CAGR 10-Years
N/A
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Total Equity
₹360.1B
CAGR 3-Years
20%
CAGR 5-Years
17%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Total Equity
₹329.2B
CAGR 3-Years
15%
CAGR 5-Years
14%
CAGR 10-Years
11%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Total Equity
₹778.2B
CAGR 3-Years
14%
CAGR 5-Years
12%
CAGR 10-Years
11%
Lupin Ltd
NSE:LUPIN
Total Equity
₹172B
CAGR 3-Years
13%
CAGR 5-Years
6%
CAGR 10-Years
6%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Total Equity
₹84.5B
CAGR 3-Years
12%
CAGR 5-Years
9%
CAGR 10-Years
10%
No Stocks Found

Neuland Laboratories Ltd
Glance View

Neuland Laboratories Ltd., with its roots firmly planted in the bustling pharmaceutical sector of India, presents a captivating narrative of innovation and strategic growth. Founded in 1984 by Dr. D.R. Rao, the venture initially embarked on its journey by manufacturing Active Pharmaceutical Ingredients (APIs), essential components that power numerous medical treatments. Situated in Hyderabad, the company swiftly carved out a niche by focusing on complex and high-value APIs, earning a reputation for quality and reliability. This strategy enabled Neuland to establish long-standing relationships with prominent generic pharmaceutical companies across the globe. As the world of pharmaceuticals evolved, so did Neuland's approach to business. The company shifted gears to not just produce APIs but also ventured into Contract Research and Manufacturing Services (CRAMS), capitalizing on the growing demand for customized pharmaceutical development and production services. This not only diversified their revenue streams but also aligned them with the needs of various pharmaceutical innovators striving for precision and customization in their drug formulations. With a commitment to regulatory compliance and a robust infrastructural foundation, Neuland Laboratories continues to bolster its position in the market, marrying its time-honored expertise in chemistry with cutting-edge technological advancements to drive profitability and sustain its international footprint.

NEULANDLAB Intrinsic Value
8 193.28 INR
Overvaluation 46%
Intrinsic Value
Price

See Also

What is Neuland Laboratories Ltd's Total Equity?
Total Equity
16.2B INR

Based on the financial report for Sep 30, 2025, Neuland Laboratories Ltd's Total Equity amounts to 16.2B INR.

What is Neuland Laboratories Ltd's Total Equity growth rate?
Total Equity CAGR 5Y
17%

Over the last year, the Total Equity growth was 16%. The average annual Total Equity growth rates for Neuland Laboratories Ltd have been 22% over the past three years , 17% over the past five years .

Back to Top